Neal Palejwala, MD
Ophthalmology · Phoenix, AZNPI 1871720755
Payments from drug & device makers
Across 560 payments — averaging $1120.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$197K
- Novartis$154K
- Aerie Pharmaceuticals, Inc.$71K
- Genentech, Inc.$63K
- Regeneron$47K
- F. Hoffmann-la Roche AG$34K
- plus $61K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 47 | $196,882 |
| Novartis | 14 | $154,188 |
| Aerie Pharmaceuticals, Inc. | 9 | $70,569 |
| Genentech, Inc. | 15 | $63,213 |
| Regeneron | 106 | $47,125 |
| F. Hoffmann-la Roche AG | 111 | $34,023 |
| AbbVie(2 entities) | 26 | $18,178 |
| Astellas Pharma Global Development | 3 | $10,657 |
| Regeneron Healthcare Solutions, Inc. | 63 | $9,182 |
| Alimera Sciences, Inc. | 23 | $6,419 |
| Genentech USA, Inc. | 41 | $5,904 |
| Mallinckrodt Enterprises LLC | 1 | $4,500 |
| Eyepoint US, Inc. | 6 | $1,638 |
| Notal Vision, Inc. | 3 | $777 |
| Bausch & Lomb Americas Inc. | 25 | $642 |
| Astellas Pharma US Inc | 15 | $624 |
| Dutch Ophthalmic, USA | 4 | $472 |
| Biogen | 12 | $433 |
| Alcon | 6 | $336 |
| Apellis Pharmaceuticals, Inc. | 9 | $325 |
| ANI Pharmaceuticals, Inc. | 8 | $251 |
| Rxsight Inc | 2 | $239 |
| Carl Zeiss Meditec USA, Inc. | 2 | $201 |
| Eyevance Pharmaceuticals LLC | 1 | $171 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $121 |
| Ivantis, Inc | 1 | $109 |
| Dompe US, Inc. | 1 | $95 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Harrow Eye, LLC | 1 | $30 |
| Amgen | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $23 |
| Spark Therapeutics, Inc. | 1 | $19 |
How this compares
$627,439 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Phoenix
- Ramin SchadluPhoenix$1.8M
- John CasonPhoenix$1.7M
- Benjamin HellerPhoenix$1.1M
- Pravin DugelPhoenix$479K
- Robert GrossPhoenix$268K
- Sujit IttyPhoenix$216K
- Jung DaoPhoenix$213K
- Karim JamalPhoenix$101K
- Nishi ShahPhoenix$92K
- Thomas WolfPhoenix$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.